Summit Therapeutics Inc.SMMTNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +5.11% | +5.17% | +10.68% | +5.72% | +1.38% |
| Weighted Average Shares Diluted Growth | +5.11% | +5.17% | +4.90% | +2.31% | +1.38% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -34.32% | -100.00% | +0.00% | -100.00% | -100.00% |
| Inventory Growth | +0.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +114.62% | +117.12% | -5.21% | -47.95% | +72.46% |
| Book Value per Share Growth | +376.05% | +640.56% | +20.16% | -58.47% | +67.17% |
| Debt Growth | -93.20% | -94.11% | -94.89% | -83.30% | +114.79% |
| R&D Expense Growth | +164.06% | +66.05% | +575.44% | +247.51% | +186.56% |
| SG&A Expenses Growth | +24.12% | +35.34% | +2483.18% | +405.51% | +439.29% |